Open AccessEvaluation of a Novel In-house HIV-1 Genotype Drug Resistance Assay using Clinical Samples in China
Author(s) -
Peijie Gao,
Fang Yu,
Xiaozhen Yang,
Dan Li,
Yonglei Shi,
Yan Wang,
Fujie Zhang
Publication year - 2022
Publication title -
current hiv research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.561
H-Index - 52
eISSN - 1873-4251
pISSN - 1570-162X
DOI - 10.2174/1570162x19666210910144433
Subject(s) - genotyping , reverse transcriptase , virology , genotype , drug resistance , human immunodeficiency virus (hiv) , biology , medicine , gene , polymerase chain reaction , genetics
Background: HIV drug resistance poses a major challenge for anti-retroviral treatment(ART) and the prevention and control of HIV epidemic. Objective: The study aims to establish a novel in-house assay with high efficiency, named AP inhousemethod, that would be suitable for HIV-1 drug resistance detection in China. Methods: An in-house HIV-1 genotyping method was used to sequence the partial pol gene from60 clinical plasma samples; the results of our test were compared with a commercial ViroSeqHIV-1 genotyping system. Results : Among sixty samples, 58(96.7%) were successfully amplified by AP in-house method,five of them harbored viral load below 1,000 copies/ml. The genotype distribution was 43.1% CRF07_BC (25/58), 39.7% CRF01_AE (23/58), 6.9% CRF55_01B (4/58), 5.2% subtype B (3/58) and5.2% CRF08_BC (3/58). Compared with that of the ViroSeq system, the consistent rate of these nucleotidesand amino acids obtained by AP in-house method was up to 99.5 ± 0.4% and 99.5 ±0.4%, respectively. A total of 290 HIV-1 drug resistance mutations were identified by two methods,including 126 nucleoside reverse transcriptase inhibitors (NRTIs), 145 non-nucleoside reversetranscriptase inhibitors (NNRTIs) and 19 protease inhibitors (PIs) resistance mutations. Out ofthem, 94.1% (273/290) were completely concordant between the AP in-house method and the ViroSeqsystem. Conclusion: Overall, the evaluation of AP in-house method provided comparable results to thoseof the ViroSeq system on diversified HIV-1 subtypes in China.